• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Aytu BioPharma Inc.

    6/13/25 2:09:06 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AYTU alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    AYTU BIOPHARMA, INC

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    054754858

    (CUSIP Number)


    06/09/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    054754858


    1Names of Reporting Persons

    LYTTON LAURENCE W
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    454,505.00
    6Shared Voting Power

    52,100.00
    7Sole Dispositive Power

    454,505.00
    8Shared Dispositive Power

    52,100.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    506,605.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The shares of the Common Stock reported herein consist of 506,605 shares of Common Stock and warrants to purchase 2,216,666 shares of Common Stock, subject to a 4.99% beneficial ownership limitation. The percentages reported in this Schedule 13G are based on 8,976,914 shares of Common Stock outstanding as of June 9, 2025, as reported in the Current Report Form 8-K filed by the Issuer on June 9, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    AYTU BIOPHARMA, INC
    (b)Address of issuer's principal executive offices:

    7900 East Union Avenue, Suite 920, Denver, CO 80237
    Item 2. 
    (a)Name of person filing:

    Laurence W. Lytton
    (b)Address or principal business office or, if none, residence:

    467 CENTRAL PARK WEST, NEW YORK, NY 10025
    (c)Citizenship:

    United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    054754858
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    506,605
    (b)Percent of class:

    5.6%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    454,505

     (ii) Shared power to vote or to direct the vote:

    52,100

     (iii) Sole power to dispose or to direct the disposition of:

    454,505

     (iv) Shared power to dispose or to direct the disposition of:

    52,100

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    LYTTON LAURENCE W
     
    Signature:/s/ Laurence W. Lytton
    Name/Title:Reporting person
    Date:06/13/2025
    Get the next $AYTU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AYTU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AYTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Disbrow Jarrett bought $24,999 worth of shares (16,666 units at $1.50), increasing direct ownership by 130% to 29,462 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      6/10/25 3:06:06 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Disbrow Joshua R. bought $99,999 worth of shares (66,666 units at $1.50), increasing direct ownership by 77% to 153,257 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      6/10/25 3:04:30 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Disbrow Joshua R. bought $19,500 worth of shares (15,000 units at $1.30), increasing direct ownership by 21% to 86,591 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/3/25 1:35:04 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Disbrow Jarrett bought $24,999 worth of shares (16,666 units at $1.50), increasing direct ownership by 130% to 29,462 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      6/10/25 3:06:06 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Disbrow Joshua R. bought $99,999 worth of shares (66,666 units at $1.50), increasing direct ownership by 77% to 153,257 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      6/10/25 3:04:30 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Large owner Nantahala Capital Management, Llc

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      6/9/25 4:31:42 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

      DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.The fireside chat will take place at 10:00 a.m. Eastern Time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/health2025/ or directly at https://lythampartners.com/health2025/aytu. A replay of the fireside chat will also be available through same links.1

      1/6/25 9:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Disclosure Notification

      DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION STYLED WITMER V. ARMISTICE CAPITAL LLC, ET AL., NO. 2022-0807-MTZ (THE "ACTION").TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF AYTU BIOPHARMA, INC. ("AYTU" OR THE "COMPANY") (NASDAQ:AYTU) AS OF OCTOBER 9, 2024 (THE "RECORD DATE") ("CURRENT AYTU SHAREHOLDERS").YOU ARE HEREBY NOTIFIED that the Settling Parties to the Action have reached a settlement ("Settlement") to resolve the issues raised in the Action against Defendants

      12/3/24 11:45:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

      DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year."We are honored to be recognized for the fourth consecutive year as a member of the Deloitte Technology Fast 500 list of the most rapidly growing companies," commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "During fiscal 2024, we continued to successfully reposition

      11/22/24 9:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Financials

    Live finance-specific insights

    See more
    • Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

      Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30, 2024Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flowRyan Selhorn promoted to Chief Financial OfficerCompany to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / November 13, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today ann

      11/13/24 4:05:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

      DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 13, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, November 13, 2024, at 4:30 p.m. Eastern timeCall-in Information: Interested parties can access the conference call by dialing (877) 545-

      11/6/24 5:20:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

      Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 millionFull year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023$20.0 million cash balance at June 30, 2024Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levelsCompany to host conference call and webcast today, September 26, 2026, at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / September 26, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel ther

      9/26/24 4:15:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Leadership Updates

    Live Leadership Updates

    See more
    • Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

      Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.Mr. Disbrow will conduct a presentation and subsequently open the floor to questions. Please submit your questions in advance to [email protected]'s presentation will be on Thursday, December 7th at 1:10pm ET. To register to stream the presentation live, visit this LINK or visit the Company's website.If attendees are not able to

      11/30/23 8:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Appoints Mark Oki as Chief Financial Officer

      ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer effective January 17, 2022. Mr. Oki will serve as a member of Aytu's executive committee and will report to Josh Disbrow, chief executive officer. Mr. Oki will provide leadership and oversight of the company's financial operations and planning, accounting, information technology and select other functions."On behalf of the entire company, I am delighted to welcome Mark to Aytu and look forward to partnering with him as we

      1/4/22 8:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

      - Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company -- Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline -- Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year -- Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET -ENGLEWOOD, CO / ACCESSWIRE / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commerciali

      5/17/21 4:01:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Aytu BioPharma Inc.

      SCHEDULE 13G - AYTU BIOPHARMA, INC (0001385818) (Subject)

      6/13/25 2:09:06 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Aytu BioPharma Inc.

      SCHEDULE 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      6/9/25 4:31:39 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)

      6/9/25 4:30:51 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Aytu BioPharma with a new price target

      Cantor Fitzgerald initiated coverage of Aytu BioPharma with a rating of Overweight and set a new price target of $11.00

      3/30/21 6:27:35 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aytu BioPharma Inc.

      SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      11/13/24 5:36:50 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aytu BioPharma Inc.

      SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      6/18/24 4:30:29 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aytu BioPharma Inc. (Amendment)

      SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      2/13/24 4:25:46 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care